Table 1.
Sample demographic and clinical characteristic
| Sample group | SF (n = 22) | NSF (n = 24) |
|---|---|---|
| Age, mean ± SD, years | 19.5 ± 9.5 | 24.0 ± 12.1 |
| Age at epilepsy onset, mean ± SD, years | 15.2 ± 6.2 | 20.5 ± 13.0 |
| Duration of epilepsy, mean ± SD, years | 4.4 ± 6.1 | 3.8 ± 5.6 |
| Interictal spike (Y/N), n | 12/10 | 13/11 |
| Seizure frequency before LEV, times/month | 3.0 ± 5.9 | 3.4 ± 4.3 |
| MRI findings (Y/N), n | 6/16 | 12/12 |
| Seizure circadian rhythm (day/night/both), n | 8/8/6 | 8/5/11 |
| Temporal lobe epilepsy (Y/N), n | 5/17 | 11/13 |
| Comorbidity (Y/N), n | 8/14 | 7/17 |
| Family history (Y/N), n | 2/20 | 0/24 |
| LEV initiation to the last seizure, days | 6.5 ± 5.3 | 8.1 ± 7.8 |
| Seizure type, n | ||
| Focal | 10 | 7 |
| Generalized | 11 | 15 |
| Combined two types | 1 | 2 |
| Maintenance dose of LEV, mg BID a | 568.2 ± 290.5 | 760.4 ± 260.4 |
| Follow‐up time, month | 20.2 ± 6.5 | 20.2 ± 6.7 |
BID, twice daily; LEV, levetiracetam; MRI, magnetic resonance imaging; N, No; NSF, Not seizure‐free group; SD, standard deviation; SF, Seizure‐free group; Y, Yes
a
vs. control, P < 0.05. For continuous variables, independent‐sample t tests or Mann–Whitney U test was carried out. For categorical variables, χ2 tests were carried out